14 results on '"Howieson D"'
Search Results
2. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial.
- Author
-
Lovera JF, Kim E, Heriza E, Fitzpatrick M, Hunziker J, Turner AP, Adams J, Stover T, Sangeorzan A, Sloan A, Howieson D, Wild K, Haselkorn J, Bourdette D, Lovera, Jesus F, Kim, Edward, Heriza, Elizabeth, Fitzpatrick, Mary, Hunziker, James, and Turner, Aaron P
- Published
- 2012
- Full Text
- View/download PDF
3. Natural history of cognitive decline in the old old.
- Author
-
Howieson DB, Camicioli R, Quinn J, Silbert LC, Care B, Moore MM, Dame A, Sexton G, Kaye JA, Howieson, D B, Camicioli, R, Quinn, J, Silbert, L C, Care, B, Moore, M M, Dame, A, Sexton, G, and Kaye, J A
- Published
- 2003
- Full Text
- View/download PDF
4. Neurologic function in the optimally healthy oldest old.
- Author
-
Howieson, D. B, Holm, L. A., Kaye, J. A., Oken, B. S., and Howieson, J.
- Published
- 1993
- Full Text
- View/download PDF
5. Brain volume loss in MCI predicts dementia.
- Author
-
Erten-Lyons D, Howieson D, Moore MM, Quinn J, Sexton G, Silbert L, and Kaye J
- Published
- 2006
- Full Text
- View/download PDF
6. Motor slowing precedes cognitive impairment in the oldest old.
- Author
-
Camicioli, R., Howieson, D., Oken, B., Sexton, G., and Kaye, J.
- Published
- 1998
- Full Text
- View/download PDF
7. Pathologies Underlying Longitudinal Cognitive Decline in the Oldest Old.
- Author
-
Nguyen MT, Mattek N, Woltjer R, Howieson D, Silbert L, Hofer S, Kaye J, Dodge H, and Erten-Lyons D
- Subjects
- Aged, 80 and over, Dementia pathology, Female, Humans, Longitudinal Studies, Male, Neuropsychological Tests, Oregon, Brain pathology, Cognitive Dysfunction pathology, Neurofibrillary Tangles, Plaque, Amyloid
- Abstract
Background: Understanding contributions of different brain pathologies to domain-specific cognitive trajectories in the oldest old is crucial to guide future intervention studies., Methods: Two-hundred-twenty Oregon Alzheimer's Disease Center research participants who were cognitively intact at entry were followed on average for 7.3 years with annual neuropsychological testing until death (mean age, 93.7 y) and autopsy. Mixed effects models examined the relationship between trajectories in memory, verbal fluency, and mini-mental state examination (MMSE) and pathology (neurofibrillary tangles, neuritic plaques, gross infarcts, hippocampal sclerosis, Lewy bodies, APOE genotype, age at death, and years of education). The association between the MMSE trajectory and pathologic variables were examined using a Poisson model with MMSE errors as outcomes given the nonlinear distribution of MMSE scores., Results: Memory trajectory was associated with the APOε4 allele (P=0.006). Verbal fluency trajectory was associated with gross infarcts (P=0.008). MMSE trajectory was associated with high Braak scores (P=0.03), gross infarcts (P<0.0001), hippocampal sclerosis (P=0.003), moderate neuritic plaques (P=0.04), and the APOε4 allele (P=0.02)., Conclusions: The association between trajectory of decline in global cognitive scores and multiple brain pathologies highlights the importance of accounting for comorbid pathologies in therapeutic trials aimed at one specific pathology in the oldest old. Only the APOε4 allele showed an association with memory decline, despite accounting for Alzheimer's disease pathology, suggesting that APOE may be involved in mechanisms beyond amyloid metabolism in its role in memory. Further studies are needed to examine the role of APOE in brain aging.
- Published
- 2018
- Full Text
- View/download PDF
8. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline.
- Author
-
Silbert LC, Nelson C, Howieson DB, Moore MM, and Kaye JA
- Subjects
- Aged, Aged, 80 and over, Brain pathology, Disease Progression, Female, Follow-Up Studies, Gait, Humans, Longitudinal Studies, Male, Middle Aged, Organ Size, Risk Factors, Aging pathology, Cognition Disorders pathology, Dementia pathology, Movement Disorders pathology, Nerve Fibers, Myelinated pathology
- Abstract
Background: White matter hyperintensity (WMH) change on brain MRI is observed with increased frequency in the elderly and has been independently associated with neurologic decline. The degree to which the location and rate of volume increase in WMH affects other structural brain changes along with cognitive and motor performance over time may determine subsequent degrees of risk for dementia and other syndromes of aging., Methods: One hundred four cognitively intact men and women followed longitudinally for up to 13 years underwent at least three MRIs with corresponding annual cognitive and neurologic assessments. Brain volume, ventricular CSF (vCSF), and total periventricular (PV) and subcortical WMH volumes were measured. Progression of MRI volumes was examined in relation to rates of cognitive, motor, and cerebral volume change based on slopes of outcomes., Results: Higher initial total and PV WMH volume was associated with total WMH, PV WMH, and vCSF progression, and with increased time and number of steps to walk 30 feet. Progression of PV WMH volume was associated with increased time to walk 30 feet. Progression of subcortical WMH volume was associated with decreased performance on logical memory testing and increased rate of vCSF volume change., Conclusion: Increased total and periventricular (PV) white matter hyperintensity (WMH) burden and progression of PV WMH burden are associated with decreased gait performance over time, while progression of subcortical WMH volume is associated with memory decline in cognitively intact elderly. Greater progression of WMH burden is associated with an increased risk of memory and gait dysfunction, and thus should not be considered a benign process.
- Published
- 2008
- Full Text
- View/download PDF
9. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline.
- Author
-
Dodge HH, Zitzelberger T, Oken BS, Howieson D, and Kaye J
- Subjects
- Aged, 80 and over, Brain drug effects, Brain physiopathology, Cerebral Hemorrhage chemically induced, Cognition Disorders physiopathology, Cohort Studies, Dementia physiopathology, Disease Progression, Double-Blind Method, Drugs, Chinese Herbal adverse effects, Female, Ginkgolides adverse effects, Humans, Male, Memory Disorders drug therapy, Memory Disorders physiopathology, Memory Disorders prevention & control, Models, Statistical, Neuroprotective Agents administration & dosage, Neuropsychological Tests, Nootropic Agents administration & dosage, Nootropic Agents adverse effects, Pilot Projects, Placebos, Risk Reduction Behavior, Treatment Outcome, Cognition Disorders prevention & control, Dementia prevention & control, Drugs, Chinese Herbal administration & dosage, Ginkgolides administration & dosage
- Abstract
Objective: To assess the feasibility, safety, and efficacy of Ginkgo biloba extract (GBE) on delaying the progression to cognitive impairment in normal elderly aged 85 and older., Methods: Randomized, placebo-controlled, double-blind, 42-month pilot study with 118 cognitively intact subjects randomized to standardized GBE or placebo. Kaplan-Meier estimation, Cox proportional hazard, and random-effects models were used to compare the risk of progression from Clinical Dementia Rating (CDR) = 0 to CDR = 0.5 and decline in episodic memory function between GBE and placebo groups., Results: In the intention-to-treat analysis, there was no reduced risk of progression to CDR = 0.5 (log-rank test, p = 0.06) among the GBE group. There was no less of a decline in memory function among the GBE group (p = 0.05). In the secondary analysis, where we controlled the medication adherence level, the GBE group had a lower risk of progression from CDR = 0 to CDR = 0.5 (HR = 0.33, p = 0.02), and a smaller decline in memory scores (p = 0.04). There were more ischemic strokes and TIAs in the GBE group (p = 0.01)., Conclusions: In unadjusted analyses, Ginkgo biloba extract (GBE) neither altered the risk of progression from normal to Clinical Dementia Rating (CDR) = 0.5, nor protected against a decline in memory function. Secondary analysis taking into account medication adherence showed a protective effect of GBE on the progression to CDR = 0.5 and memory decline. Results of larger prevention trials taking into account medication adherence may clarify the effectiveness of GBE. More stroke and TIA cases observed among the GBE group requires further study to confirm.
- Published
- 2008
- Full Text
- View/download PDF
10. Trajectories of brain loss in aging and the development of cognitive impairment.
- Author
-
Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF, and Kaye JA
- Subjects
- Aged, Aged, 80 and over, Alzheimer Disease diagnosis, Alzheimer Disease etiology, Alzheimer Disease pathology, Atrophy diagnosis, Atrophy etiology, Atrophy pathology, Brain pathology, Cognition Disorders diagnosis, Cohort Studies, Disease Progression, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging methods, Magnetic Resonance Imaging trends, Male, Middle Aged, Aging pathology, Cerebral Ventricles pathology, Cognition Disorders etiology, Cognition Disorders pathology
- Abstract
Background: The use of volumetric MRI as a biomarker for assessing transitions to dementia presumes that more rapid brain loss marks the clinical transition from benign aging to mild cognitive impairment (MCI). The trajectory of this volume loss relative to the timing of the clinical transition to dementia has not been established., Methods: The authors annually evaluated 79 healthy elderly subjects for up to 15 consecutive years with standardized clinical examinations and volumetric brain MRI assessments of ventricular volume. During the study period, 37 subjects developed MCI. A mixed effects model with a change point modeled the pattern of brain volume loss in healthy aging compared with subjects diagnosed with MCI., Results: The brain loss trajectory of subjects developing MCI during follow-up differed from healthy aging in a two-phase process. First, the annual rate of expansion of ventricular volume decreased with age; however, the annual rates of expansion were greater in those who developed cognitive impairment during follow-up compared with those who did not. Further, subjects who developed MCI had an acceleration of ventricular volume expansion approximately 2.3 years prior to clinical diagnosis of MCI., Conclusions: Ventricular expansion is faster in those developing mild cognitive impairment years prior to clinical symptoms, and eventually a more rapid expansion occurs approximately 24 months prior to the emergence of clinical symptoms. These differential rates of preclinical atrophy suggest that there are specific windows for optimal timing of introduction of dementia prevention therapies in the future.
- Published
- 2008
- Full Text
- View/download PDF
11. Brain volume preserved in healthy elderly through the eleventh decade.
- Author
-
Mueller EA, Moore MM, Kerr DC, Sexton G, Camicioli RM, Howieson DB, Quinn JF, and Kaye JA
- Subjects
- Aged, Aged, 80 and over, Atrophy, Female, Humans, Male, Mental Status Schedule, Neuropsychological Tests, Organ Size, Aging pathology, Brain pathology
- Abstract
Objective: To determine which brain regions lose volume with aging over time in healthy, nondemented elderly., Background: Cross-sectional studies suggest widespread loss of brain volume with aging. These studies may be biased by significant numbers of preclinically demented elderly in the oldest comparison groups. Longitudinal studies may allow closer determination of the effect of aging unaffected by dementia., Methods: Quantitative volumetric MRI was performed annually on 46 healthy subjects older than age 65 who had maintained cognitive health a mean of 5 years. Comparisons (analysis of variance) were made of rates of volume loss (slopes) divided into 11 young-old (mean age, 70 years), 15 middle-old (mean age, 81 years), and 20 oldest-old (mean age, 87 years) subjects. Regions of interest included CSF spaces, lobar regions, and limbic-subcortical regions., Results: There were significant differences between groups in intracranial, total brain, left hemisphere, right hemisphere, temporal lobe, basilar-subcortical region, and hippocampus volumes, with oldest-old subjects showing the smallest volumes, followed by middle-old and young-old subjects. Oldest-old subjects had significantly greater subarachnoid volumes than the younger groups. There were no significant differences in rates of change of regions of interest across age groups., Conclusions: After age 65 there is minimal brain volume loss observed over time in healthy elderly. Brain volume differences seen cross-sectionally, at any age, likely reflect small, constant rates of volume loss with healthy aging. Healthy oldest-old subjects do not show greater rates of brain loss compared with younger elderly, suggesting that large changes seen in cross-sectional studies reflect the presence of preclinical dementia in older groups.
- Published
- 1998
- Full Text
- View/download PDF
12. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia.
- Author
-
Kaye JA, Swihart T, Howieson D, Dame A, Moore MM, Karnos T, Camicioli R, Ball M, Oken B, and Sexton G
- Subjects
- Aged, Aged, 80 and over, Discriminant Analysis, Female, Forecasting, Humans, Magnetic Resonance Imaging, Male, Reference Values, Aging psychology, Dementia diagnosis, Hippocampus pathology, Temporal Lobe pathology
- Abstract
Objective: To determine initial locus and rate of degeneration of temporal lobe structures (total lobe, hippocampus and parahippocampus) in preclinical dementia., Background: Postmortem studies suggest that the earliest changes in Alzheimer's disease are neurofibrillary tangle formation in hippocampus and adjacent cortex. MRI volume analysis of temporal lobe structures over time in subjects prior to developing dementia may allow the identification of when these processes begin, the rate they develop, and which areas are key to symptom development., Methods: 30 nondemented (NoD), healthy, elderly individuals enrolled in a prospective study of healthy aging evaluated annually over a mean of 42 months. Twelve subjects with subsequent cognitive decline were assigned to the preclinical dementia group (PreD). All 120 annual MRI studies analyzed by volumetric techniques assessed group differences in temporal lobe volumes and rates of brain loss., Results: NoD as well as PreD subjects had significant, time-dependent decreases in hippocampal and parahippocampal volume. Rates of volume loss between the groups did not significantly differ. PreD cases had significantly smaller hippocampi when asymptomatic. Parahippocampal volume did not differ between PreD and NoD cases. Significant time-dependent temporal lobe atrophy was present only in PreD., Conclusions: Hippocampal and parahippocampal atrophy occurs at a similar rate regardless of diagnostic group. Those who develop dementia may have smaller hippocampi to begin with, but become symptomatic because of accelerated loss of temporal lobe volume. Temporal lobe volume loss may mark the beginning of the disease process within six years prior to dementia onset.
- Published
- 1997
- Full Text
- View/download PDF
13. Talking while walking: the effect of a dual task in aging and Alzheimer's disease.
- Author
-
Camicioli R, Howieson D, Lehman S, and Kaye J
- Subjects
- Aged, Aged, 80 and over, Aging psychology, Female, Humans, Language Tests, Male, Reference Values, Aging physiology, Alzheimer Disease physiopathology, Alzheimer Disease psychology, Verbal Behavior, Walking
- Abstract
We determined the effects of distraction on gait in healthy elderly subjects and Alzheimer's disease (AD) patients. The effects of simultaneous performance of a verbal fluency task (effect of reciting male or female names) on the time and number of steps taken to walk 30 feet were compared using a repeated-measures design with between-group comparison between community-dwelling healthy old old (oOld; n = 20; mean age +/- SD, 86 +/- 4.4), healthy young old (yOld; n = 23; mean age +/- SD, 72 +/- 3.6), and probable AD subjects without parkinsonism (n = 15; mean age +/- SD, 74 +/- 13). AD patients slowed more than the yOld (p = 0.005) and the oOld (p = 0.002). The yOld and oOld did not differ from each other (p = 0.68). Mean (+/-SD) differences in time were as follows: yOld, -2.2 +/- 1.9; oOld, -1.6 +/- 2.0; AD, -7.1 +/- 9.2 seconds. The change in steps did not differ between groups. Walking speed of AD patients slowed more than that of elderly subjects during the dual task. This may contribute to the risk of falls in AD.
- Published
- 1997
- Full Text
- View/download PDF
14. Attention deficit in Alzheimer's disease is not simulated by an anticholinergic/antihistaminergic drug and is distinct from deficits in healthy aging.
- Author
-
Oken BS, Kishiyama SS, Kaye JA, and Howieson DB
- Subjects
- Aged, Analysis of Variance, Diphenhydramine pharmacology, Female, Humans, Male, Methylphenidate pharmacology, Middle Aged, Reaction Time, Reference Values, Aging psychology, Alzheimer Disease psychology, Attention drug effects, Histamine Antagonists pharmacology, Parasympatholytics pharmacology
- Abstract
Objective: To evaluate attention deficit in Alzheimer's disease (AD) and its relationship to attention deficits associated with aging and with medications altering alertness., Methods: Ten patients with probable AD, 10 healthy old controls, and 15 young controls performed a covert orienting of spatial attention task. Young controls performed the task an additional time after ingestion of diphenhydramine 1 mg/kg. Reaction times were obtained following valid, neutral, and invalid cues., Results: In all groups, the reaction times were shortest for the validly cued stimuli and longest for the invalidly cued stimuli. Additionally, the AD patients performed disproportionately worse following the invalid cue than did the control groups. Young controls given diphenhydramine had decreased subjective alertness, performed worse than they did before drug but better than the old controls or AD patients, and had no disproportionate impairment with the invalid cue., Conclusions: AD patients have disproportionate problems shifting spatial attention compared with age-matched controls. Impaired attentional performance in AD cannot be simulated in young subjects by ingestion of a combined antihistamine/anticholinergic agent at a dose sufficient to produce significant changes in alertness.
- Published
- 1994
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.